<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">2602</id>
  <title>T3D2561</title>
  <common-name>Chloroquine</common-name>
  <description>Chloroquine is only found in individuals that have used or taken this drug. It is a prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [PubChem]The mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. nside red blood cells, the malarial parasite must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasite cell.During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals.Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products.</description>
  <cas>54-05-7</cas>
  <pubchem-id>2719</pubchem-id>
  <chemical-formula>C18H26ClN3</chemical-formula>
  <weight>319.181530</weight>
  <appearance>White to slightly yellow, crystalline powder (A619).</appearance>
  <melting-point>289°C</melting-point>
  <boiling-point></boiling-point>
  <density></density>
  <solubility>10.6 mg/L</solubility>
  <specific-gravity></specific-gravity>
  <flash-point></flash-point>
  <vapour-pressure></vapour-pressure>
  <route-of-exposure>InhalationCompletely absorbed from gastrointestinal tract</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>The mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites.  nside red blood cells, the malarial parasite must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasite cell.During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals.Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products.</mechanism-of-toxicity>
  <metabolism>Completely absorbed from gastrointestinal tract.  Chloroquine is partially metabolized; the major metabolite is desethylchloroquine. Desethylchloroquine also has antiplasmodial activity, but is slightly less active than chloroquine. Bisdesethylchloroquine, which is a carboxylic acid derivative, and several other unidentified metabolites are also formed in small amounts (A625).Route of Elimination: Excretion of chloroquine is quite slow, but is increased by acidification of the urine.Half Life: 1-2 months</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>3, not classifiable as to its carcinogenicity to humans. (L135)</carcinogenicity>
  <use-source>For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis (A308).</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Possible heath effects include an irreversible retinal damage, visual disturbances,  nyctalopia; scotomatous vision with field defects of paracentral, pericentral ring types, and typically temporal scotomas, nerve type deafness; tinnitus, reduced hearing in patients with preexisting auditory damage. Other effects include  pleomorphic skin eruptions, skeletal muscle myopathy, hypotension, electrocardiographic change as well as neuropsychiatric changes including psychosis, delirium, personality changes and depression (RxList, A308).</health-effects>
  <symptoms>Convulsive seizures. Mild and transient headache. </symptoms>
  <treatment>Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis (at home, before transportation to the hospital) or gastric lavage until the stomach is completely emptied. If finely powdered, activated charcoal is introduced by stomach tube, after lavage, and within 30 minutes after ingestion of the antimalarial, it may inhibit further intestinal absorption of the drug. To be effective, the dose of activated charcoal should be at least five times the estimated dose of chloroquine ingested. Convulsions, if present, should be controlled before attempting gastric lavage. (L1712)</treatment>
  <created-at type="dateTime">2009-07-05T03:00:49Z</created-at>
  <updated-at type="dateTime">2026-05-14T16:43:53Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Chloroquine</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C07625</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>3638</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id>D002738</ctd-id>
  <stitch-id>Chloroquine</stitch-id>
  <drugbank-id>DB00608</drugbank-id>
  <pdb-id>CLQ</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1</moldb-smiles>
  <moldb-formula>C18H26ClN3</moldb-formula>
  <moldb-inchi>InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)</moldb-inchi>
  <moldb-inchikey>WHTVZRBIWZFKQO-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">319.872</moldb-average-mass>
  <moldb-mono-mass type="decimal">319.181525554</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>4.63</logp>
  <hmdb-id>HMDB14746</hmdb-id>
  <chembl-id>CHEMBL76</chembl-id>
  <chemspider-id>2618</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Andersag, H., Breitner, S.and Jung, H.; U S . Patent 2,233,970; March 4,1941; assigned to&lt;br /&gt;
Winthrop Chemical Company, Inc.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002087</chemdb-id>
  <dsstox-id>DTXSID2040446</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00001540</susdat-id>
  <iupac>7-chloro-N-[5-(diethylamino)pentan-2-yl]quinolin-4-amine</iupac>
  <moldb-polar-surface-area>28.16</moldb-polar-surface-area>
  <moldb-refractivity>96.42300000000002</moldb-refractivity>
  <moldb-polarizability>37.28790341691832</moldb-polarizability>
  <moldb-rotatable-bond-count>8</moldb-rotatable-bond-count>
  <moldb-acceptor-count>3</moldb-acceptor-count>
  <moldb-donor-count>1</moldb-donor-count>
  <moldb-pka-strongest-acidic nil="true"/>
  <moldb-pka-strongest-basic>10.324447273782475</moldb-pka-strongest-basic>
  <moldb-physiological-charge>2</moldb-physiological-charge>
  <moldb-number-of-rings>2</moldb-number-of-rings>
  <moldb-alogps-logp>5.28</moldb-alogps-logp>
  <moldb-alogps-logs>-4.26</moldb-alogps-logs>
  <moldb-alogps-solubility>1.75e-02 g/l</moldb-alogps-solubility>
</compound>
